US case series: FTRD® in IBD patients

FTRD® presents as a promising new treatment modality for IBD patients, achieving 100% technical success, no postoperative complications and no residual lesions or recurrence

Key findings

• 100% technical success rate (5/5 cases)
• Histologically confirmed full-thickness resection in all patients
• No adverse events (no bleeding, no perforation, no postoperative complications)
• No residual lesions or recurrence at mean follow-up of 7.8 ± 4.5 months

Study details

• Single-center, retrospective case series; June 2020 – July 2022 (Allegheny General Hospital, Pittsburgh, PA, USA)
• 5 adult patients (mean age 66.4 ± 6.8 years) with ulcerative colitis (inflammatory bowel disease / IBD)
• Aim: Evaluation of safety and efficacy of EFTR using the FTRD® System in IBD patients with challenging colorectal lesions unsuitable for conventional endoscopic resection
• Indications: Fibrotic, non-lifting colorectal polyps
• Polyp locations: descending colon (n=3), rectum (n=1), transverse colon (n=1)
• Mean polyp size: 25 ± 5 mm

Khataniar H, Desai A, Kochhar GS. Initial Experience With Safety and Efficacy of Endoscopic Full-Thickness Resection in Patients With Inflammatory Bowel Disease: A Case Series. ACG Case Rep J. 2024 Dec 20;11(12):e01571. doi: 10.14309/crj.0000000000001571.

This content is intended exclusively for healthcare professionals. Please refer to the instructions for use and note country-specific approvals and indications.